CINGW (Cingulate Inc. Warrants)
Insider Trading Activity
Every open-market purchase and sale reported by CINGW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Thomas Jeffrey Hargroves | Director | Buy | — | — |
| 2026-05-08 | Raul R. Silva | EVP and CSO | A | — | — |
| 2026-03-11 | Matthew Brams | EVP and Chief Medical Officer | MIXED | — | — |
| 2026-03-11 | Raul R. Silva | EVP and CSO | MIXED | — | — |
| 2026-03-11 | Nilay Dahyabhai Patel | EVP, CLO and CCO | MIXED | — | — |
| 2026-03-11 | Jennifer L. Callahan | EVP and CFO | MIXED | — | — |
| 2026-03-11 | Shane J. Schaffer | Chief Executive Officer | MIXED | — | — |
| 2026-02-10 | Jennifer L. Callahan | SVP and CFO | Buy | — | — |
| 2026-02-10 | Matthew Brams | EVP and Chief Medical Officer | Buy | — | — |
| 2026-02-10 | Shane J. Schaffer | Chief Executive Officer | Buy | — | — |
| 2026-02-10 | Peter J. Werth | Director | Buy | — | — |
| 2026-01-05 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-11-10 | Bryan Wade Downey | Chief Commercial Officer | A | — | — |
| 2025-11-10 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-07-10 | Nilay Dahyabhai Patel | CLO and CCO | A | — | — |
| 2025-07-09 | Laurie Myers | EVP and COO | A | — | — |
| 2025-07-09 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-07-09 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2025-07-09 | Jennifer L. Callahan | SVP and CFO | A | — | — |
| 2025-07-09 | Shane J. Schaffer | Chief Executive Officer | A | — | — |
| 2025-07-01 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-06-23 | Peter J. Werth | Director | A | — | — |
| 2025-06-23 | JOHN A ROBERTS | Director | A | — | — |
| 2025-06-23 | Bryan Jay Lawrence | Director | A | — | — |
| 2025-06-23 | Jeffrey S Ervin | Director | A | — | — |
| 2025-02-20 | Shane J. Schaffer | Chief Executive Officer | A | — | — |
| 2025-02-20 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2025-02-20 | Jennifer L. Callahan | SVP and CFO | A | — | — |
| 2025-02-20 | Laurie Myers | EVP and COO | A | — | — |
| 2025-02-20 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-01-22 | Jennifer L. Callahan | SVP and CFO | A | — | — |
| 2025-01-22 | Shane J. Schaffer | Chief Executive Officer | A | — | — |
| 2025-01-22 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2025-01-22 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-01-22 | Laurie Myers | EVP and COO | A | — | — |
| 2025-01-07 | Raul R. Silva | EVP and CSO | A | — | — |
| 2025-01-07 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2024-10-01 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2024-10-01 | Raul R. Silva | EVP and CSO | A | — | — |
| 2024-08-19 | Laurie Myers | EVP and COO | Sell | — | — |
| 2024-07-02 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2024-07-02 | Raul R. Silva | EVP and CSO | A | — | — |
| 2024-06-13 | Matthew Brams | EVP and Chief Medical Officer | A | — | — |
| 2024-06-13 | Raul R. Silva | EVP and CSO | A | — | — |
| 2024-06-13 | Bryan Jay Lawrence | Director | A | — | — |
| 2024-06-13 | Shane J. Schaffer | Chief Executive Officer | A | — | — |
| 2024-06-13 | Jennifer L. Callahan | SVP and CFO | A | — | — |
| 2024-06-13 | Peter J. Werth | Director | A | — | — |
| 2024-06-13 | Laurie Myers | EVP and COO | A | — | — |
| 2024-06-13 | JOHN A ROBERTS | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | EVP and General Counsel | 194,846 | — |
| — | Director | 164,318 | — |
| — | EVP and CFO | 156,606 | — |
| — | Director | 117,541 | — |
| — | Director | 105,768 | — |
| — | EVP and CFO | 20,388 | — |
| — | Chief Executive Officer | 17,210 | — |
| — | EVP and Chief Medical Officer | 9,182 | — |
| — | EVP and CSO | 6,473 | — |
| — | EVP, CLO and CCO | 3,389 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CINGW quote page; the site-wide leaderboard is on the insider transactions hub.